Scheduled to be operational by September 2025, the plant will produce plastic materials for diagnostic testing
Premix’s facility in Rajamäki, Finland. (Credit: Premix Group)
Premix Group has secured a $79.9m contract from the US Department of Defence and the Department of Health and Human Services to build a plastic compound manufacturing factory in North Carolina, US.
The plant will produce plastic materials for diagnostic testing.
Scheduled to be operational by September 2025, the plant will be built in Gaston County, centrally located in the region of advanced manufacturing in the southeast US.
The deal was funded through the American Rescue Plan Act to allow and support the growth of the US domestic industrial base for crucial medical supplies.
Premix Group managing director Hanna Ristola said: “Our hard work in building resilient supply chains, high product quality and consistency pays off as the US government awarded Premix the deal to build a local manufacturing site.”
The agreement will benefit the firm to secure vital diagnostic supplies in the US and better serve Premix’s global customers.
The plant will produce plastic compounds suitable for pipette tips to meet the growing demand and high-quality criteria for diagnostic tests.
The additional production capacity will result in more than 200 million Covid-19 PCR tests being performed each month.
Premix will provide local production and services for faster delivery speed and high reliability to North American clients.
The facilities will employ roughly 30-35 people in Gaston County, North Carolina, as well as support additional employment with service providers and subcontractors both during construction and while operational.
Premix president and CEO Jari-Matti Mehto said: “The new capacity will improve Premix’s global supply capability and mitigate risks in global supply chains.
“With the new U.S. factory, we will improve our ability to serve our customers in the important US market.
“We are extremely excited about this opportunity to help secure a supply of critical diagnostic materials in the United States.
“Our solutions meet strict standards for quality and cost-efficiency and provide valuable benefits to our new and existing customers.”